Flexion Therapeutics, a Woburn, Mass.-based company that advances drug candidates through clinically meaningful proof of concept and beyond, completed a $33m Series A financing round led by Versant Ventures with participation from founding investors 5AM Ventures and Sofinnova Partners.
Established in 2007, the company provides a new vehicle to define the potential of drug candidates, advance candidates of demonstrated potential through commercialization, and optimize portfolio value.
The funds will be used to advance a number of promising drug candidates through clinically meaningful proof of concept and beyond.
FinSMEs
16/10/2009